tbuckley/cabot-search huggingface dataset:
Prognostic value of pathologic tumor response in ewing sarcoma (ES).
Authors: Micheal Gary Keeney, Safia K. Ahmed, Karen Fritchie, Andrew Folpe, Nadia N. Laack
Journal: Journal of Clinical Oncology (2014)

e21022 Background: Although European studies suggest pathologic response correlates with survival in ES, the value of pathologic response has not been confirmed in North American treatment regimens. The purpose of this study was to analyze the effect of tumor response on event free survival (EFS) and overall survival (OS) outcomes in patients with newly diagnosed ES. Methods: Mayo Clinic tumor registry was utilized to identify 109 patients with ES seen at Mayo Clinic from 1983-2003 who underwent surgery as a part of local therapy. 56 were excluded due to insufficient pathologic specimens leaving 53 patients in whom tumor response was analyzable. All specimens were re-reviewed by an expert sarcoma pathologist. Modified Huvos grading system was used for response classification (Grade 1=<50%,2=50-89%,3=90-99%,4=100% necrosis). Records were reviewed for factors relevant to prognosis, survival, and local control and data was analyzed by Kaplan-Meier methods using JMP statistical software. Results: The median age at diagnosis was 16 years (range 3-54). All patients received chemotherapy prior to surgery. 71% of patients presented with extremity tumors, 6% with pelvic tumors, and 23% with axial tumors. Median follow-up for surviving patients was 8.8 yrs (range: 0.7-20). Complete pathologic response was seen in 1 patient. Grade I necrosis was most common (62%), followed by grade 2 (23%) and grade 3 (13%).The 5 yr OS and EFS were 73% and 64% respectively. No association was seen between treatment response and gender or age or treatment era (1983-1993, 1993-2003). Extraosseous and extremity location were associated with slightly higher rates of pathologic response but the results did not reach statistical significance (p=0.07, p=0.14, respectively). There was no significant association between per cent necrosis or necrosis grade and EFS or OS. Grade II tumor response had slightly improved 5-yr OS (81% vs 68%, p=ns) and 5-yr EFS (82% vs 59%, p=ns). Conclusions: Tumor response defined as greater than 50% necrosis is associated with a trend toward improved EFS and OS in patients with ES. Further study with larger numbers is needed to confirm these results.
Treatment of patients waitlisted for liver transplant with all‐oral direct‐acting antivirals is a cost‐effective treatment strategy in the United States
Authors: Aijaz Ahmed, Stevan A. Gonzalez, George Cholankeril, Ryan B. Perumpail, Justin McGinnis, Sammy Saab, Rachel Beckerman, Zobair M. Younossi
Journal: Hepatology (2017)

All‐oral direct acting antivirals (DAAs) have been shown to have high safety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant (LT). However, there is limited empirical evidence comparing the health and economic outcomes associated with treating patients pre‐LT versus post‐LT. The objective of this study was to analyze the cost‐effectiveness of pre‐LT versus post‐LT treatment with an all‐oral DAA regimen among HCV patients with hepatocellular carcinoma (HCC) or decompensated cirrhosis (DCC). We constructed decision‐analytic Markov models of the natural disease progression of HCV in HCC patients and DCC patients waitlisted for LT. The model followed hypothetical cohorts of 1,000 patients with a mean age of 50 over a 30‐year time horizon from a third‐party US payer perspective and estimated their health and cost outcomes based on pre‐LT versus post‐LT treatment with an all‐oral DAA regimen. Transition probabilities and utilities were based on the literature and hepatologist consensus. Sustained virological response rates were sourced from ASTRAL‐4, SOLAR‐1, and SOLAR‐2. Costs were sourced from RedBook, Medicare fee schedules, and published literature. In the HCC analysis, the pre‐LT treatment strategy resulted in 11.48 per‐patient quality‐adjusted life years and $365,948 per patient lifetime costs versus 10.39 and $283,696, respectively, in the post‐LT arm. In the DCC analysis, the pre‐LT treatment strategy resulted in 9.27 per‐patient quality‐adjusted life years and $304,800 per patient lifetime costs versus 8.7 and $283,789, respectively, in the post‐LT arm. As such, the pre‐LT treatment strategy was found to be the most cost‐effective in both populations with an incremental cost‐effectiveness ratio of $74,255 (HCC) and $36,583 (DCC). Sensitivity and scenario analyses showed that results were most sensitive to the utility of patients post‐LT, treatment sustained virological response rates, LT costs, and baseline Model for End‐Stage Liver Disease score (DCC analysis only). Conclusion : The timing of initiation of antiviral treatment for HCV patients with HCC or DCC relative to LT is an important area of clinical and policy research; our results indicate that pre‐LT treatment with a highly effective, all‐oral DAA regimen provides the best health outcomes and is the most cost‐effective strategy for the treatment of HCV patients with HCC or DCC waitlisted for LT. (H epatology 2017;66:46–56).
Production of TRAIL by Multiple Myeloma Cells: a Potential Prediction Marker for Skeletal-Related Events
Authors: Yawara Kawano, Shikiko Ueno, Masahiro Abe, Yoshitaka Kikukawa, Hiromichi Yuki, Kenichi Iyama, Yutaka Okuno, Hiroaki Mitsuya, Hiroyuki Hata
Journal: Blood (2010)
Radioactive Decay
Authors: Venkatesh L. Murthy, Leslee J. Shaw, Brahmajee K. Nallamothu
Journal: Circulation (2017)

n the United States, single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI) accounts for the overwhelming majority of noninvasive imaging procedures for stable ischemic heart disease. 1 Most contemporary SPECT MPI is performed using blood-flow radiotracers labeled with technetium-99m (Tc-99m), which have supplanted thallium-201, an older radiotracer.Tc-99m offers several advantages including superior image quality, lower radiation exposure, and higher overall diagnostic accuracy because of greater specificity. 2Estimates suggest up to 17 million doses of Tc-99m are used annually in the United States, with the majority used in cardiac stress testing.However, 9 unplanned shutdowns at critical facilities totaling 50 months of downtime between 2008 and 2015 have made the supply chain for Tc-99m increasingly fragile. 1 We and others demonstrated that these shutdowns may have had important clinical consequences by creating Tc-99m shortages that lead to increased rates of unnecessary, downstream cardiac catheterization and higher radiation exposure. 3,4nfortunately, multiple, simultaneous challenges to the worldwide supply chain for Tc-99m may impact the care of patients and cardiologists' decision making.In this article, we briefly review the reasons behind these trends and new solutions being proposed.
MPs call for £1.5bn to plug gap in adult social care funding
Authors: Anne Gulland
Journal: BMJ (2017)

MPs have called on the chancellor of the exchequer to pledge an extra £1.5bn (€1.7bn; $1.8bn) for adult social care in England when he unveils the budget on Wednesday 8 March.

In an interim report on adult social care, the select committee on communities and local government warned that adult social care needed immediate extra funding, because it faced a shortfall of between £1.3bn and £1.9bn over the 2017-18 financial year.1 MPs are calling on the chancellor, Philip Hammond, to use the 2019-20 tranche of the Better Care Fund to plug the funding gap.

The report’s authors said that since 2010, when adult social care budgets were cut, councils across England had made efficiencies and savings, “but we do not believe this is sustainable and agree that councils have moved from doing ‘more for less’ to ‘less for less.’” The report added, “There is evidence that …
T Cell Receptor Gene Repertoire Restriction in Chronic Lymphocytic Leukemia with Stereotyped IGHV4–34/IGKV2–30 Antigen Receptors
Authors: Anna Vardi, Andreas Agathangelidis, Evangelia Stalika, Millaray Marincevic, Maria Karypidou, Achilles Anagnostopoulos, Chrysoula Belessi, Nikos Darzentas, Richard Rosenquist, Kostas Stamatopoulos
Journal: Blood (2012)
Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets.
Authors: Thomas Buchner, Wolfgang E. Berdel, Claudia Schoch, Torsten Haferlach, Joelle Tchinda, Susanne Schnittger, Wolfgang Kern, Albrecht Reichle, Peter Staib, Hubert L. Serve, Wolf-Dieter Ludwig, Maria Cristina Sauerland, Achim Heinecke, Bernhard Josef Wormann, Wolfgang Hiddemann
Journal: Blood (2006)
Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.
Authors: Daniela Cilloni, Monica Pradotto, Francesca Messa, Francesca Arruga, Enrico Bracco, Sonia Carturan, Chiara Maffè, Emanuela Messa, Antonia Rotolo, Elisabetta Greco, Ilaria Iacobucci, Thea Kalebic, Roberto Bernardoni, Fabrizio Pane, Giovanni Martinelli, Michele Baccarani, Giuseppe Saglio
Journal: Blood (2009)
Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience
Authors: Hassan A. Aljasem, Hans A. Messner, Jeffrey H. Lipton, Dennis Dong Hwan Kim, Auro Viswabandya, Santhosh Thyagu, Uday Deotare, Fotios V. Michelis
Journal: Blood (2016)
Comparing outcomes in robotic-assisted and conventional laparoscopic endometrioid endometrial cancer: A study of practice patterns in 42,197 patients over 2 years.
Authors: Jill Ashley Gadzinski, Alexander Olawaiye, Madeleine Courtney-Brooks, John T. Comerci, Joseph L. Kelley, Marilyn Huang, Sushil Beriwal, Paniti Sukumvanich, Jeff Feng-Hsu Lin
Journal: Journal of Clinical Oncology (2015)

e16524 Background: Robotic surgery has become widely adopted in the treatment of endometrial cancer despite data suggesting higher cost and mixed clinical benefit. A comparison of robotic-assisted laparoscopy (ROB) with conventional laparoscopy (LAP) in the treatment of endometrial cancer to identify implications in clinical practice is needed. Methods: Patients who underwent minimally invasive surgery alone for non-metastatic endometrioid endometrial adenocarcinoma were identified from the National Cancer Database. Univariate analysis was done with chi-squared tests with Bonferroni-Holm correction, and independent associations were assessed using binary logistic regression modeling. Results: A total of 42,197 patients were identified and 82.6% had stage I disease. Conversion to laparotomy was lower in ROB than LAP (2 vs 10%). LAP was associated with a median 5 day advantage in earlier time-to-surgery (26 vs. 31, p< 0.001) but had no significant difference in 30-day mortality (p= 0.14). Median surgical stay was less than 2 days for both groups. On multivariable analysis, Caucasian/Asian race, insured (non-Medicaid) status, residing in areas with high education levels, increased travel distance to treatment facility, higher-grade cancer, and treatment at academic/comprehensive community cancer center were independently associated with ROB rather than LAP (all p< 0.05). Controlling for significant patient, disease, facility and treatment factors, multivariable analysis found treatment with ROB was independently predictive of undergoing radical hysterectomy (OR 1.83, 1.45-2.30) and lymphadenectomy (OR 1.70, 1.56-1.84). ROB had a higher nodal yield (9 vs. 5 median nodes, p< 0.0005) without a significant difference in positive node detection rate (6 vs. 5.4%, p= 0.15). Conclusions: Robotic-assisted staging compared to conventional laparoscopy of endometrial cancer is associated with more advanced/radical procedures in this large, national cohort but appears to be underutilized in patients of lower socioeconomic status. Longer follow-up is needed to see if the radicality associated with ROB translates into survival benefit.
A Novel MBT-Containing Protein, Hemp, Plays Essential Roles In Skeletal Formation and Hematopoietic Stem Cell Function.
Authors: Phyo Wai Htun, Keiyo Takubo, Hideaki Oda, Feng Ma, Kenjiro Kosaki, Kateri A. Moore, Norimasa Yamasaki, Kohichiro Tsuji, Ihor R. Lemischka, Toshio Suda, Hiroaki Honda
Journal: Blood (2010)
Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome
Authors: Fabian Beier, Ulrich Germing, Guntram Büsche, Patrick Ziegler, Stefan Wilop, Lucia Vankann, Norbert Gattermann, Uwe Platzbecker, Aristoteles Giagounidis, Katharina S. Götze, Wolf-Karsten Hofmann, Detlef Haase, Hans Kreipe, Jens Panse, Tim H. Brümmendorf
Journal: Blood (2013)
Randomized phase III trial of adjuvant epicirubicin (E) followed by cyclophosphamide, methotrexate, and fluorouracil (CMF) or CMF followed by E in patients with N<sup>-</sup> or ≤ 3 N<sup>+</sup> rapidly proliferating breast cancer (RPBC)
Authors: D. Amadori, F. Schittulli, A. Paradiso, E. Scarpi, P. Sismondi, A. Ravaioli, A. Rocca, R. Maltoni, P. Serra, R. Silvestrini
Journal: Journal of Clinical Oncology (2009)

560 Background: Antimetabolites are active in proliferating cells, and the adjuvant schedule CMF is highly effective in RPBC, whereas the sequential administration of doxorubicin (D) and CMF is superior to CMF–&gt;D, especially in indolent tumors. In a phase III study, we evaluated whether adjuvant E followed by CMF is superior to the inverse sequence in RPBC. Methods: Patients with N-, T &gt; 1 cm or ≤ 3 N + and any T RPBC (defined by thymidine labeling index or grade or S-phase or Ki67/MIB1) were randomized to receive E (100 mg/m2 i.v. d 1, q 21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m2 i.v. d 1 and 8, q 28 days for 4 cycles) (arm A) or CMF followed by E (arm B) or CMF (600, 40, 600 mg/m2 i.v. d 1 and 8, q 28 days for 6 cycles) (arm C). Arm C was closed after the EBCTCG 2000 meta-analysis (data not shown). The main endpoint was overall survival (OS), and the study had 80% power to detect a 7% absolute increase in 5-year OS with 400 patients per arm. Results: From November 1997 to December 2004, 1066 patients were enrolled (arms A/B/C: 440/438/188): N- 53%, estrogen receptor positive 63%, grade 3, 77%. At a median follow up of 69 months, 5-year disease-free survival was 80% in both arms (A and B) (p = 0.93, logrank test), with adjusted hazard ratio (AHR) 0.99 (95% CI 0.73–1.33, Cox model), and OS was 91% in arm A and 93% in arm B (p = 0.66, logrank), with AHR 0.88 (95% CI 0.58–1.35, Cox model). Adverse events were similar, apart from a small increase in grade 4 neutropenia in arm B. Conclusions: No relevant differences in clinical outcome were observed with the 2 different sequences. Further subgroup analyses are ongoing to verify the efficacy of each sequence as a function of biomolecular and hormonal profiles. No significant financial relationships to disclose.
Stable Titania Nanostructures on Stainless Steel Coronary Stent Surface for Enhanced Corrosion Resistance and Endothelialization
Authors: Chandini C. Mohan, Aleena Mary Cherian, Sujish Kurup, John Joseph, Manitha B. Nair, Maniyal Vijayakumar, Shantikumar V. Nair, Deepthy Menon
Journal: Advanced Healthcare Materials (2017)

Stainless steel (SS) coronary stents continue to present risk of in‐stent restenosis that impact its long term safety and efficacy. The present work focuses on developing a drug‐free and polymer‐less surface on coronary stents by utilizing a titania (TiO 2 ) nanotexturing approach through hydrothermal processing, that will offer improved stent performance in vivo. Mechanically stable and durable nanotextured coatings are obtained on SS stents that also offer good corrosion resistance. In vitro vascular cell (endothelial and smooth muscle cells) studies on surface modified SS show preferential rapid endothelialization with enhanced nitric oxide production and reduce smooth muscle cell proliferation, in comparison to unmodified SS. In vivo evaluation of the nanotextured stents after subcutaneous implantation in rabbits show reduced irritability and minimal localized inflammatory response. These beneficial effects suggest that the stable, easily scalable titania nanosurface modification strategy on coronary stent surfaces can be a much cheaper alternative to drug eluting stents in addressing in‐stent restenosis.
Impact of Global and Gene-Specific DNA Methylation Pattern in Relapsed Multiple Myeloma Patients Treated with Bortezomib
Authors: Carlos Fernández de Larrea, Beatriz Martin-Antonio, María Teresa Cibeira, Alfons Navarro, Natalia Tovar, Tania Díaz, Laura Rosiñol, Mariano Monzó, Alvaro Urbano-Izpizua, Joan Blade
Journal: Blood (2011)
Phase 1 Clinical Study of Adoptive Immunotherapy with Delayed Infusion of Alloanergized Donor T Cells to Improve Immune Reconstution after Haploidentical Stem Cell Transplantation.
Authors: Jeff Davies, Marcos De Lima, Laurence Cooper, Thomas Spitzer, Neena Kapoor, Lisa Brennan, Peter Thall, John McMannis, Richard Champlin, Lee Nadler, Eva Guinan
Journal: Blood (2008)
MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells
Authors: Sebastiano Rontauroli, Ruggiero Norfo, Valentina Pennucci, Roberta Zini, Samantha Ruberti, Elisa Bianchi, Simona Salati, Zelia Prudente, Chiara Rossi, Vittorio Rosti, Paola Guglielmelli, Giovanni Barosi, Alessandro M. Vannucchi, Enrico Tagliafico, Rossella Manfredini
Journal: Blood (2016)
Neuropsychological (NP) Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adult Patients with Sickle Cell Disease (SCD).
Authors: Elliott Vichinsky, J. Gold, R. Rule, M. Weiner, B. Eggleston, A. Muma, L. Neumayr, S. Lieff, D. Bessman, K. Kalinyak, L. De Castro, T. Harrington, A. Hussein, C. Johnson, L. McMahon, E. Orringer, C. Rutherford, D. Armstrong
Journal: Blood (2007)
Clinical observation of next-generation photodynamic therapy (NGPDT) for advanced non-small cell lung cancer.
Authors: Li Jun Li
Journal: Journal of Clinical Oncology (2013)

e19028 Background: Clinical observation of next-generation photodynamic therapy (NGPDT) for advanced non-small cell lung cancer (NSCLC). Methods: Through pathology or cytology diagnosis, 66 cases of advanced non-small cell lung cancer patients were selected and randomly divided into two groups. The Next Generation Photodynamic Therapy (NGPDT) group had 32 patients. Photosensitizer was administered on a dosage of 2 mg per kilogram of body weight, wherein two-thirds via ultrasonic atomization inhalation and one-third via oral intake. After the irradiation target(s) were determined, optical fiber for laser treatment purposes was guided into lung tumor(s) via interstitial procedure, percutaneous puncture under precious laser navigation, irradiation light intensity was 200 J/cm 2 , irradiation power was 1,000 mw, activation was then started and lasted for eight to ten minutes, laser irradiation into tumor was two to five centimeters in length, irradiation could be performed phase by phase (sub-paragraph treatment) based on tumor size or irradiations could be performed repeatedly. While in the mean time in the chemotherapy/radiotherapy group (external beam radiotherapy + whole body chemotherapy) 34 cases were observed, 15 MV X ray radiation therapy irradiation field covers primary lung tumor lesion(s) and mediastinal lymphatic drainage area, dosage was 65-70 Gy, on every first day in a week of radiotherapy, 20 mg cisplatin was administered via intravenous application. Results: In the NGPDT group and simultaneous radiotherapy/chemotherapy group, one and two years survival rate were 93.75%, 70.60% and 68.75, 32.35% respectively (P &lt;0.05). The complete remission rate and partial remission rate were 56.20% and 21.30%, rate of the NGPDT group was significantly higher than that of the corresponding radiotherapy and chemotherapy group, the difference was statistically significant (P &lt;0.05). Conclusions: NGPDT can prolong survival in patients with advanced NSCLC, improving their quality of life; it is one of the most effective measures for advanced non-small cell lung cancer treatment.
Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up,
Authors: Michael A. Thompson, Caimiao Wei, Ann M Moyer, Julie M Cunningham, Luhua Wang, Luis Fayad, Lei Feng, Maria Alma Rodriguez, Fernando Cabanillas, Hagop M. Kantarjian, Larry W Kwak, Jorge E Romaguera
Journal: Blood (2011)
Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome
Authors: Simon J. Bowman, Colin C. Everett, John L. O'Dwyer, Paul Emery, Costantino Pitzalis, Wan‐Fai Ng, Colin T. Pease, Elizabeth J. Price, Nurhan Sutcliffe, Nagui S. T. Gendi, Frances C. Hall, Sharon P. Ruddock, Catherine Fernandez, Catherine Reynolds, Claire T. Hulme, Kevin A. Davies, Christopher J. Edwards, Peter C. Lanyon, Robert J. Moots, Euthalia Roussou, Ian P. Giles, Linda D. Sharples, Michele Bombardieri
Journal: Arthritis & Rheumatology (2017)

To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that included health economic analysis. Anti-Ro-positive patients with primary SS, symptomatic fatigue, and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014. Patients were centrally randomized to receive either intravenous (IV) placebo (250 ml saline) or IV rituximab (1,000 mg in 250 ml saline) in 2 courses at weeks 0, 2, 24, and 26, with pre- and postinfusion medication including corticosteroids. The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale. Other outcome measures included salivary and lacrimal flow rates, quality of life, scores on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index, symptoms of ocular and overall dryness, pain, globally assessed disease activity, and cost-effectiveness. All 133 patients who were randomized to receive placebo (n = 66) or rituximab (n = 67) were included in the primary analysis. Among patients with complete data, 21 of 56 placebo-treated patients and 24 of 61 rituximab-treated patients achieved the primary end point. After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]). There were no significant improvements in any outcome measure except for unstimulated salivary flow. The mean ± SD costs per patient for rituximab and placebo were £10,752 ± 264.75 and £2,672 ± 241.71, respectively. There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group). The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population.
Minimal Residual Disease Detection by Real Time PCR of the Dominant-Negative Isoform of Ikaros in Patients with Acute Lymphoblastic Leukemia.
Authors: Takayuki Tabayashi, Fumihiko Ishimaru, Koichi Nakase, Hiromi Nakashima, Itaru Kataoka, Mitsune Tanimoto
Journal: Blood (2006)
Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.
Authors: Deepti Behl, Kay M. Ristow, Svetomir Markovic, Thomas E. Witzig, Thomas M. Habermann, Joseph P. Colgan, Ivana N.M. Micallef, Patrick B. Johnston, Stephen Ansell, Christopher A. Yasenchak, Rajnish Manchanda, Luis F. Porrata
Journal: Blood (2006)